Morrison Briggs's Form 4 filing
Syndax Pharmaceuticals IncSNDX · filed Apr 5, 2022
- Accession no.
- 0001562180-22-003223
- Filed
- Apr 5, 2022
- Trade date
- Apr 1-4, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.82M. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0001562180-22-003383 (Apr 13, 2022). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Morrison BriggsCIK 0001654430 | Director, Officer (President, Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2022 | Common Stock | SSaleDisposed | −6,000 | $17.44F2 | −$104,640 | 42,336 | Direct | |
| Apr 1, 2022 | Common Stock | SSaleDisposed | −24,500 | $17.44F3 | −$427,280 | 17,836 | Direct | |
| Apr 1, 2022 | Common Stock | MOption exerciseAcquired | +70,545 | $10.90 | +$768,940.5 | 88,381 | Direct | |
| Apr 1, 2022 | Common Stock | SSaleDisposed | −70,545 | $17.46F4 | −$1,231,715.7 | 17,836 | Direct | |
| Apr 4, 2022 | Common Stock | MOption exerciseAcquired | +3,128 | $10.90 | +$34,095.2 | 20,964 | Direct | |
| Apr 4, 2022 | Common Stock | SSaleDisposed | −3,128 | $18.29F5 | −$57,211.12 | 17,836 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2022 | Common Stock | MOption exerciseDisposed | −70,545 | $0.00 | $0 | 0 | Direct | |
| Apr 4, 2022 | Common Stock | MOption exerciseDisposed | −3,128 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale prices ranged from $17.21 to $17.62.
Referenced by the price of 1 transaction in Table I.
- F3
The sale prices ranged from $17.19 to $17.66.
Referenced by the price of 1 transaction in Table I.
- F4
The sale prices ranged from $17.18 to $17.69.
Referenced by the price of 1 transaction in Table I.
- F5
The sale prices ranged from $17.75 to $19.17.
Referenced by the price of 1 transaction in Table I.